Articles On Arc Exploration (ASX:ARX)

ASX health sector rises 4.3% for the week in rotation back to sector, while broader market rises 0.8%  Ramsay’s shares lift as investors react positively to news of a transformation strategy for its Australian private hospitals business Mo...

The team at Bell Potter have just released fresh analysis on ASX small-cap stock Aroa Biosurgery Limited (ASX: ARX).  It is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and d...

Tylah Tully speaks with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward about the company’s first HY FY26 results, which delivered NZ$44.9 million in revenue driven by strong growth in its Myriad product. The company reported its fourt...

ASX struggles into the positive to add 0.14% Gold stocks, info tech lead gains Banks drag as BEN’s compliance issues bite   Gold gains outweigh banking ballast The banking sector took the wind out of the ASX’s sails today, suffering a spo...

Aroa Biosurgery (ASX: ARX) has reported total product revenue of NZ$44.9 million for the first six months of financial year 2026, representing growth of 14% on the previous corresponding period.

With 12 months of consistent positive cash flow, Aroa Biosurgery no longer needs to lodge quarterly reports Monash IVF’s bidder will have to pay more  Pacific Edge positions itself for reimbursement resumption   Aroa Biosurgery’s (ASX:ARX...

ASX closes 3.60 points lower after falling in afternoon session Mayne Pharma falls ~32% after Australian government opposes proposed takeover ASX gold stocks lead materials sector higher after bullion prices rebound 2% overnight    The AS...

Seasoned global healthcare executive Paul Shearer to join Aroa Biosurgery as a non-executive director Shearer spent more than 30 years at Fisher & Paykel Healthcare, playing a key role in its US expansion The appointment comes as long-...

The ASX health sector moved up 1.30% for the week, while the broader market inched up 0.12% Aroa recorded fourth consecutive quarter of positive net cash flow with Myriad breaking records Orthocell raised $30 million in oversubscribed plac...

ASX closes 0.86% higher to reach a new 100-day high after hitting an intraday record  Australia’s unemployment rate climbs to four-year high of 4.5% in September, up from revised 4.3% in August Rate sensitive sectors including real estate,...

The NSW Supreme Court has, in effect, ruled against Cosette’s attempt to abandon its $670m takeover of Mayne Pharma Cogstate posts record quarterly sales on the back of surging demand for depression and schizophrenia testing Aroa posts st...

Aroa records fourth consecutive quarter of positive net cash flow  Highest quarter on record for high-margin Myriad products with NZ$10.2 million in sales FY26 guidance of NZ$92-100 million reaffirmed with Normalised EBITDA for FY26 of NZ$...

Regenerative medicine is a fast-growing healthcare field that harnesses the body’s natural healing ability At Monash University, the Australian Regenerative Medicine Institute is internationally recognised for pioneering research Several A...

Healthcare analysts say Aroa Biosurgery positioned to benefit from upcoming changes to US wound care market Centers for Medicare & Medicaid Services set to overhaul how skin substitutes are reimbursed, removing price driven incentives...

CSL shares have taken another 8% bath, even though brokers maintain valuations well above the current level Aroa Biosurgery says growing non-US sales should offset the impact of Trumpian tariffs “Opthea 2.0” is likely to stick with its kni...

ASX heath sector falls 0.65 % in past five days but returns 9% in July in a strong comeback  ‘Mostly pretty good’ June quarterly reporting season comes to end  Clarity Pharmaceuticals completes $203 million capital raise to institutional i...

Eye drug developer Opthea’s cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today’s sector gains after a US deal with a mystery party    The...

Energy stocks climb as oil ticks up 2pc ASX rallies late to climb 0.08pc Gold stocks slide despite recovering gold price   ASX lifts as clouds part for energy sector The ASX was in a decidedly bad mood today, hanging out in negative terri...

Morgans’ Scott Power says path to profitability is key to a successful emerging ASX health care company While innovation is important, Power says the market loses interest in companies which don’t turn a profit Wound care company Aroa Bios...

New blood test reveals hidden muscle damage in racehorses Proteomics’ OxiDx helps trainers spot injuries early and avoid breakdowns ASX-listed stocks with exposure to the animal sector.   In the high-octane world of thoroughbred racing, m...

Sales of Aroa’s high-margin Myriad family expected to further propel growth in FY26 and beyond Myriad sales were NZ$30.8 million of the total NZ$84.7m for FY25, representing 38% growth on FY24  Direct sales team momentum and growing body o...

Highlights ASX 200 closes at a new all-time high driven by strength in financials and gold sectors Major banks and insurers post solid gains, lifting the Financials Index Gold producers lead materials sector gains amid commo...

If you have a high tolerance for risk and are on the hunt for big returns, then look no further. That's because analysts at Bell Potter have named the two small cap ASX shares listed below as buys with potential to deliver outsized returns....

Highlights ASX health sector shows strength relative to broader market performance HealthCo REIT (ASX:HCW) reaches rental deferral arrangement with Healthscope receivers Aroa Biosurgery (ASX:ARX) posts inaugural full-year pr...

ASX health stocks up 1.2% over past five days while the broader market is up 0.8%  HealthCo REIT agrees to short-term partial rent deferral with troubled Healthscope and its receivers New-Zealand-based soft-tissue repair company Aroa Biosu...

Tylah Tully chats with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward on the company’s FY25 results, posting its first profit since listing on the ASX in 2020.  The company had a strong year, reporting total revenue of NZ$84.7 million...

Aroa surges to profitability in FY25 with a NZ$4.2 million normalised EBITDA profit  Reports total revenue for full year of NZ$84.7 million, up 23% and exceeding guidance Provides total revenue guidance for FY26 of NZ$92-100 million, up 10...

Tylah Tully speaks with Aroa Biosurgery (ASX:ARX) senior medical science liaison Dr Brandon Bosque about how Aroa’s groundbreaking ECM technology, backed by 100 peer-reviewed studies, is aiming to revolutionise wound care. Bosque shares the...

ASX heath sector falls 1.3%, trailing ASX 200 up 1.1% as macro picture remains uncertain but ‘little bit better’ Soft-tissue repair company Aroa Biosurgery reconfirms FY25 reported revenue guidance of NZ$81-84 million Medical imaging softe...

Soft tissue regeneration specialist Aroa Biosurgery (ASX: ARX) has posted its second consecutive quarter of positive cash flow, in a period that also saw the company reach a key milestone with over 100 published peer reviews now validating...

AROA lifts after recording its second consecutive quarter of positive cash flows from operations Full-year FY25 guidance remains unchanged at NZ$81-$84 million in total revenue Sales of AROA’s high-margin Myriad family in March top the hig...

Aroa says the real impact from the 10% US tariff imposed on New Zealand goods will be much less than that Quarter time scores show companies are kicking with the wind Dimerix shares enter trading halt ahead of licensing deal   Kiwi wounds...

Aroa’s natural healing tech from NZ pastures is reshaping tissue repair Why Ovine ECM outperforms synthetics Aroa hits positive cash flow, with profit on the horizon   Special Report: Aroa Biosurgery’s ovine-based healing technology is ga...

Aroa achieves key milestone with seven million of its soft-tissue regeneration products used in medical procedures Company has developed a range of products using its extracellular matrix technology Aroa’s products approved in more than 50...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Brian Ward, founder and CEO at Aroa Biosurgery (ASX:ARX). Aroa was founded in 2008 by...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

Highlights Aroa Biosurgery was founded in 2008 with a focus on regenerative healing through its patented AROA ECM™ technology. Despite a drop in stock value, the company reported its first quarter of positive cash flow with a NZ$1.2m s...

The ASX200 closed up 0.57% at 8,447 points. The critical trimmed mean inflation measure was up 3.2% on an annual basis, compared to 3.6% in the September quarter. This was below the 3.3% expected by market economists for the trimmed mean...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.9% to 8,475.3 points. Four ASX shares that have failed to follow the market higher today are...

Pic via Getty ImagesRadiopharmaceuticals company Telix reports sustained revenue growth in Q4 FY24 ASX health stocks fall about 2.8% over past week Neuren’s partner Acadia submits marketing authorisation application in Europe for trofine...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Aroa Biosurgery (ASX:ARX) VP of Medical Affairs Dr Adam Young about what drew him to the co...

ASX 200 lifts on tech rally, miners struggle Barrick Gold threatens Mali shutdown over shipping restrictions Bitcoin bounces back after recent slump   The ASX 200 index crept up 0.34% on Tuesday, thanks to a rally in tech following the Na...

Aroa’s Myriad shows success in lower limb reconstruction Study highlights Myriad’s efficacy and cost-saving benefits Myriad’s potential for $225m market validated by clinical results   Special Report: Aroa’s latest study reveals potential...

Highlights GR Engineering Services GNG shows impressive earnings growth, with a debt-free balance sheet. Polynovo PNV presents a compelling opportunity in wound care, despite recent price fluctuations. Aroa Biosurgery ARX delivers str...

Stockhead’s Sarah Hughan sits down with Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward to get the short end of the long story on the company’s latest news. The soft tissue repair products company has released its half yearly report...

If you have a higher than average tolerance for risk, then it could be worth considering a few small cap ASX stocks for a balanced portfolio. That's because the potential returns on offer at the small end of the market can be material. Thou...

Aroa Biosurgery product revenue up 27% to NZ$39.1 million on constant currency basis in H1 FY25 Myriad sales surge 45% in H1 FY25, accounting for 38% of total sales and 72% of direct sales mix during half Aroa expects to be operating cashf...

ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7%  Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate...

Stockhead’s Sarah Hughan sits down with Aroa Biosurgery’s (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news. The company’s biomaterial ECM technology aims to improve the rate and qualit...

  The ASX fell on new expectations for rate cuts All 11 ASX sectors fell, with real estate and healthcare hit hardest MinRes and Viva Energy dropped, Prodigy Gold rose 50pc   The ASX slid by 1.66% from near record highs in a broad sell-o...